Literature DB >> 18017

Function of human platelets during extracorporeal circulation.

V L Hennessy, R E Hicks, S Niewiarowski, L H Edmunds, R W Colman.   

Abstract

The interaction between human platelets and nonbiologic surfaces was studied during in vitro recirculation of 500 ml of fresh, heparinized human blood in four different perfusion circuits. Circuits differed in surface area (0.1 m2 or 0.9 m2) and in surface composition. No important differences were observed between standard silicone-rubber and filler-free, silicone-rubber surfaces. Platelet counts decreased to 85% of control in 0.1- m2 circuits, but retained normal sensitivity to aggregating agents and released only small amounts of platelet factor 4 (PF4). In contrast, platelet counts in 0.9-m2 circuits decreased to 20% of control within 2 min and platelet sensitivity was depressed out of proportion to the fall in platelet count. Plasma PF4 progressively increased and platelet PF4 content progressively decreased during 6 h of recirculation. The results indicate that human platelets may exist in three conditions during extracorporeal circulation. Some platelets are unaltered, some are less sensitive to aggregating agents, and others have undergone extensive release. The ratio of blood volume to surface area appears to be an important determinant of platelet-surface interaction.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 18017     DOI: 10.1152/ajpheart.1977.232.6.H622

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

1.  Extracorporeal membrane oxygenation causes loss of intestinal epithelial barrier in the newborn piglet.

Authors:  Ashish R Kurundkar; Cheryl R Killingsworth; R Britt McIlwain; Joseph G Timpa; Yolanda E Hartman; Dongning He; Rajendra K Karnatak; Mary L Neel; John P Clancy; G M Anantharamaiah; Akhil Maheshwari
Journal:  Pediatr Res       Date:  2010-08       Impact factor: 3.756

2.  Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation.

Authors:  C S Rinder; H M Rinder; B R Smith; J C Fitch; M J Smith; J B Tracey; L A Matis; S P Squinto; S A Rollins
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

3.  The new phosphodiesterase inhibitor enoximone in patients following cardiac surgery--pharmacokinetics and influence on parameters of coagulation.

Authors:  J Boldt; D Kling; H A Dieterich; P Marck; G Hempelmann
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

4.  Thromboelastography as an indicator of post-cardiopulmonary bypass coagulopathies.

Authors:  B D Spiess; K J Tuman; R J McCarthy; G A DeLaria; R Schillo; A D Ivankovich
Journal:  J Clin Monit       Date:  1987-01

5.  Carboxypeptidase N concentration during cardiopulmonary bypass in humans.

Authors:  S F Rabito; R Anders; W Soden; R A Skidgel
Journal:  Can J Anaesth       Date:  1992-01       Impact factor: 5.063

6.  Effects of continuous renal replacement therapy on intestinal mucosal barrier function during extracorporeal membrane oxygenation in a porcine model.

Authors:  Changsheng He; Shuofei Yang; Wenkui Yu; Qiyi Chen; Juanhong Shen; Yimin Hu; Jialiang Shi; Xingjiang Wu; Jieshou Li; Ning Li
Journal:  J Cardiothorac Surg       Date:  2014-04-23       Impact factor: 1.637

7.  Intestinal epithelial apoptosis initiates gut mucosal injury during extracorporeal membrane oxygenation in the newborn piglet.

Authors:  Krishnan MohanKumar; Cheryl R Killingsworth; R Britt McIlwain; Joseph G Timpa; Ramasamy Jagadeeswaran; Kopperuncholan Namachivayam; Ashish R Kurundkar; David R Kelly; Steven A Garzon; Akhil Maheshwari
Journal:  Lab Invest       Date:  2013-12-23       Impact factor: 5.662

8.  Platelet count reduction during in vitro membrane oxygenation affects platelet activation, neutrophil extracellular trap formation and clot stability, but does not prevent clotting.

Authors:  Patrick Winnersbach; Jan Rossaint; Eva M Buhl; Smriti Singh; Jonas Lölsberg; Matthias Wessling; Rolf Rossaint; Christian Bleilevens
Journal:  Perfusion       Date:  2021-01-21       Impact factor: 1.972

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.